Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Efavirenz on Tipranavir/Ritonavir PK in Healthy Volunteers
NCT02226991Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum plasma concentration at steady state, Drug concentration in plasma at 12 hours after administration and 2 more. Started Apr 2006; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02226991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226991.